公开(公告)号：US12128095B2

公开(公告)日：2024-10-29

申请号：US17672126

申请日：2022-02-15

Applicant: Pfizer Inc.

Inventor： Robert G. K. Donald ,  Annaliesa Sybil Anderson ,  Laurent Oliver Chorro ,  Jianxin Gu ,  Jin-Hwan Kim ,  Srinivas Kodali ,  Jason Arnold Lotvin ,  Justin Keith Moran ,  Rosalind Pan ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Suddham Singh ,  Ling Chu ,  Scott Ellis Lomberk ,  Karen Kiyoko Takane ,  Nishith Merchant ,  Wei Chen

IPC: A61K39/108 ,  A61K39/00 ,  A61P31/04 ,  A61P37/04 ,  C08B37/00

CPC classification number: A61K39/0258 ,  A61P31/04 ,  A61P37/04 ,  C08B37/006 ,  A61K2039/6037 ,  A61K2039/627

Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.

公开(公告)号：US11260119B2

公开(公告)日：2022-03-01

申请号：US16534457

申请日：2019-08-07

Applicant: Pfizer Inc.

Inventor： Robert G. K. Donald ,  Annaliesa Sybil Anderson ,  Laurent Oliver Chorro ,  Jianxin Gu ,  Jin-Hwan Kim ,  Srinivas Kodali ,  Jason Arnold Lotvin ,  Justin Keith Moran ,  Rosalind Pan ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Suddham Singh ,  Ling Chu ,  Scott Ellis Lomberk ,  Karen Kiyoko Takane ,  Nishith Merchant ,  Wei Chen

IPC: A61K39/108 ,  C08B37/00 ,  A61P31/04 ,  A61P37/04 ,  A61K39/00

Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.

公开(公告)号：US10982198B2

公开(公告)日：2021-04-20

申请号：US16104938

申请日：2018-08-19

Applicant: Pfizer Inc.

Inventor： Jason Arnold Lotvin ,  Annaliesa Sybil Anderson ,  Robert G. K. Donald ,  Michael James Flint ,  Narender Kumar Kalyan ,  Kathrin Ute Jansen ,  Maninder K. Sidhu ,  Justin Keith Moran ,  Mark Edward Ruppen ,  Weiqiang Sun

IPC: C07K14/33 ,  C12N1/20 ,  C12N9/10

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.

公开(公告)号：US10787652B2

公开(公告)日：2020-09-29

申请号：US14436875

申请日：2013-10-07

Applicant: Pfizer Inc.

Inventor： Jason Arnold Lotvin ,  Annaliesa Sybil Anderson ,  Robert G. K. Donald ,  Michael James Flint ,  Narender Kumar Kalyan ,  Kathrin Ute Jansen ,  Maninder K. Sidhu ,  Justin Keith Moran ,  Mark Edward Ruppen ,  Weiqiang Sun

IPC: C12N9/10 ,  C07K14/33 ,  C12N1/20

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.